Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
Int J Gynecol Cancer. 2009 Nov;19(8):1335-8. doi: 10.1111/IGC.0b013e3181a83e04.
We studied preoperative CA-125 levels of 123 patients with borderline ovarian tumors (BOTs) and performed an analysis with data of earlier published studies. CA-125 levels were compared according to histology and stage of disease. Preoperative serum CA-125 levels were significantly higher for patients with advanced stage (median, 181 U/mL; range, 413 U/mL) compared with patients with stage I (median, 28 U/mL; range, 1123 U/mL) BOTs and for patients with serous (median, 59 U/mL; range, 1119 U/mL) compared with patients with mucinous (median, 25 U/mL; range, 371 U/mL) BOTs (both P < 0.001, Mann-Whitney U test). A pooled analysis of 3 studies and the present study showed positive rates of CA-125 (value >35 U/mL) in 171 (53%) of 325 patients with BOTs. Positive rates were more often found in patients with serous (67%) compared with patients with mucinous BOTs (39%) and in patients with advanced stage (83%) compared with patients with stage I BOTs (47%) (both P < 0.001, Pearson chi(2) test). This main effect was also found for each individual study of the pooled analysis. From a clinical perspective, we believe, on base of the results of this study and the literature, that preoperative discrimination using CA-125 level is especially difficult between patients with stage I ovarian cancer and the group of patients with serous and/or advanced-stage BOTs.
我们研究了 123 例交界性卵巢肿瘤（BOT）患者的术前 CA-125 水平，并对之前发表的研究数据进行了分析。根据组织学和疾病分期比较了 CA-125 水平。与 I 期 BOT 患者（中位数，28 U/mL；范围，1123 U/mL）相比，晚期 BOT 患者（中位数，181 U/mL；范围，413 U/mL）术前血清 CA-125 水平显著升高，与粘液性 BOT 患者（中位数，25 U/mL；范围，371 U/mL）相比，浆液性 BOT 患者（中位数，59 U/mL；范围，1119 U/mL）术前血清 CA-125 水平显著升高（均 P < 0.001，Mann-Whitney U 检验）。3 项研究的汇总分析和本研究显示，325 例 BOT 患者中 CA-125（值>35 U/mL）阳性率为 171 例（53%）。浆液性 BOT 患者（67%）的阳性率高于粘液性 BOT 患者（39%），晚期 BOT 患者（83%）的阳性率高于 I 期 BOT 患者（47%）（均 P < 0.001，Pearson chi(2)检验）。汇总分析中每项研究也发现了这一主要效应。从临床角度来看，我们认为，基于这项研究和文献的结果，术前使用 CA-125 水平对 I 期卵巢癌患者和浆液性和/或晚期 BOT 患者进行区分尤其困难。
